|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0960 AUD | +3.23% |
|
-4.00% | +12.94% |
| Capitalization | 6.4Cr 4.53Cr 3.81Cr 3.48Cr 3.32Cr 6.16Cr 409.9Cr 40Cr 16Cr 197.95Cr 17Cr 17Cr 691.83Cr | P/E ratio 2024 |
-9.42x | P/E ratio 2025 | -4.7x |
|---|---|---|---|---|---|
| Enterprise value | 5.99Cr 4.23Cr 3.56Cr 3.25Cr 3.1Cr 5.76Cr 383.14Cr 38Cr 15Cr 185.02Cr 16Cr 16Cr 646.67Cr | EV / Sales 2024 |
90.4x | EV / Sales 2025 | 48.5x |
| Free-Float |
79.71% | Yield 2024 * |
-
| Yield 2025 | - |
| 06/25/06 | FDA lifts clinical hold on Nuz-001 | RE |
| 06/25/06 | Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001 | RE |
| 1 day | +3.23% | ||
| 1 week | -4.00% | ||
| Current month | +6.67% | ||
| 1 month | +17.07% | ||
| 3 months | -16.52% | ||
| 6 months | -41.82% | ||
| Current year | +12.94% |
| 1 week | 0.09 |  | 0.1 |
| 1 month | 0.08 | | 0.1 |
| Current year | 0.08 | | 0.1 |
| 1 year | 0.08 | | 0.18 |
| 3 years | 0.06 | | 0.54 |
| 5 years | 0.06 | | 0.54 |
| 10 years | 0.03 | | 0.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Thurn
CEO | Chief Executive Officer | - | 01/09/2023 |
Daniel O'Connell
DFI | Director of Finance/CFO | - | 22/04/2025 |
Stefan Ross
SEC | Corporate Secretary | - | 24/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Marcus Hughes
BRD | Director/Board Member | - | 09/05/2024 |
Sergio Duchini
CHM | Chairman | - | 17/05/2024 |
Michael Thurn
BRD | Director/Board Member | - | 31/05/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.23% | -4.00% | -40.00% | +14.29% | 4.53Cr | |
| +0.33% | -1.72% | +23.18% | +210.44% | 93TCr | |
| -0.45% | +1.44% | +55.91% | +52.76% | 59TCr | |
| +1.76% | +3.61% | +20.03% | +53.25% | 41TCr | |
| +0.08% | +1.01% | +22.24% | +29.31% | 37TCr | |
| +1.42% | +7.19% | +29.13% | +30.69% | 32TCr | |
| +1.08% | +4.32% | +31.22% | +55.61% | 31TCr | |
| +1.82% | -0.43% | +46.26% | +12.75% | 30TCr | |
| +1.32% | +5.11% | -44.29% | -37.51% | 22TCr | |
| +1.52% | -3.94% | +26.80% | +53.79% | 20TCr | |
| Average | +1.21% | +1.66% | +17.05% | +47.54% | 36.49TCr | |
| Weighted average by Cap. | +0.75% | +1.36% | +27.25% | +80.20% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8L 6L 5L 5L 4L 8L 5.39Cr 53.17L 21.11L 2.6Cr 22.31L 21.85L 9.09Cr | 15.38L 10.87L 9L 8L 8L 14.8L 9.84Cr 97.14L 38.56L 4.75Cr 40.75L 39.92L 17Cr |
| Net income | -76.73L -54.22L -45.69L -41.67L -39.78L -73.85L -49Cr -4.85Cr -1.92Cr -24Cr -2.03Cr -1.99Cr -83Cr | -1.66Cr -1.17Cr -98.8L -90.12L -86.04L -1.6Cr -106.21Cr -10Cr -4.16Cr -51Cr -4.4Cr -4.31Cr -179.26Cr |
| Net Debt | -1.07Cr -75.82L -63.89L -58.27L -55.63L -1.03Cr -69Cr -6.78Cr -2.69Cr -33Cr -2.84Cr -2.79Cr -115.91Cr | -41.81L -29.55L -24.9L -22.71L -21.68L -40.24L -27Cr -2.64Cr -1.05Cr -13Cr -1.11Cr -1.09Cr -45Cr |
Employees
4
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 0.0960 $ | +3.23% | 1,21,240 |
| 13/26/13 | 0.0930 $ | -5.10% | 43,826 |
| 12/26/12 | 0.0980 $ | -2.00% | 1,93,528 |
| 11/26/11 | 0.1000 $ | 0.00% | 2,59,354 |
| 10/26/10 | 0.1000 $ | 0.00% | 2,73,163 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0930AUD
Average target price
0.2800AUD
Spread / Average Target
+201.08%
Annual profits - Rate of surprise
- Stock Market
- Equities
- NUZ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition